دورية أكاديمية
Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial
| العنوان: | Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial |
|---|---|
| المؤلفون: | Brown, Sue, Beck, Roy, Raghinaru, Dan, Buckingham, Bruce, Laffel, Lori, Wadwa, R Paul, Kudva, Yogish, Levy, Carol, Pinsker, Jordan, Dassau, Eyal, Doyle, Francis, Ambler-Osborn, Louise, Anderson, Stacey, Church, Mei Mei, Ekhlaspour, Laya, Forlenza, Gregory, Levister, Camilla, Simha, Vinaya, Breton, Marc, Kollman, Craig, Lum, John, Kovatchev, Boris, Wadwa, R. Paul, Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Oliveri, Mary, Gondor-Fredrick, Linda, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Isganaitis, Elvira, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Andre, Camille, Piper, Molly, Lam, David, O’malley, Grenye, Ogyaadu, Selassie, Lovett, Jessica, Dadlani, Vikash, Mccrady-Spitzer, Shelly, Reid, Corey, Kumari, Kanchan, Forlenza, Greg, Alonso, G. Todd, Slover, Robert, Jost, Emily, Messer, Laurel, Berget, Cari, Towers, Lindsey, Rossick-Solis, Alex, Jacobson, Tali, Town, Marissa, Tabatabai, Ideen, Keller, Jordan, Salas, Evalina, Passman, Samantha, Campos, Tiffany, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreza-Rubin, Guillermo, Eggerman, Thomas, Green, Neal, Doyle Iii, Francis, Renard, Eric, Cobelli, Claudio, Reznik, Yves, Janicek, Robert, Gabrielson, Deanna, Belle, Steven, Castle, Jessica, Green, Jennifer, Legault, Laurent, Willi, Steven, Wysham, Carol |
| المساهمون: | University of Virginia, Jaeb Center for Health Research, Stanford University School of Medicine CA, USA, Joslin Diabetes Center, Barbara Davis Center for Childhood Diabetes (BDC), University of Colorado Anschutz Aurora, Department of Health Sciences Research Mayo Clinic (HSR), Mayo Clinic, Icahn School of Medicine at Mount Sinai New York (MSSM), William Sansum Diabetes Center (SDRI), Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS), Harvard University, William Sansum Diabetes Research Institute (SDRI), Stanford University, The International Diabetes Closed Loop (iDCL), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier) |
| المصدر: | ISSN: 0149-5992. |
| بيانات النشر: | HAL CCSD American Diabetes Association |
| سنة النشر: | 2020 |
| المجموعة: | Archive ouverte HAL (Hyper Article en Ligne, CCSD - Centre pour la Communication Scientifique Directe) |
| مصطلحات موضوعية: | MESH: Adolescent, MESH: Adult, MESH: Insulin, MESH: Insulin Infusion Systems, MESH: Intention to Treat Analysis, MESH: Male, MESH: Middle Aged, MESH: Prognosis, MESH: Treatment Outcome, MESH: United States, MESH: Young Adult, MESH: Aged, MESH: Blood Glucose, MESH: Blood Glucose Self-Monitoring, MESH: Diabetes Mellitus, Type 1, MESH: Female, MESH: Humans, MESH: Hypoglycemia, MESH: Injections, Subcutaneous, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism |
| الوصف: | International audience ; OBJECTIVE Limited information is available about glycemic outcomes with a closed-loop control (CLC) system compared with a predictive low-glucose suspend (PLGS) system. RESEARCH DESIGN AND METHODS After 6 months of use of a CLC system in a randomized trial, 109 participants with type 1 diabetes (age range, 14–72 years; mean HbA1c, 7.1% [54 mmol/mol]) were randomly assigned to CLC (N = 54, Control-IQ) or PLGS (N = 55, Basal-IQ) groups for 3 months. The primary outcome was continuous glucose monitor (CGM)-measured time in range (TIR) for 70–180 mg/dL. Baseline CGM metrics were computed from the last 3 months of the preceding study. RESULTS All 109 participants completed the study. Mean ± SD TIR was 71.1 ± 11.2% at baseline and 67.6 ± 12.6% using intention-to-treat analysis (69.1 ± 12.2% using per-protocol analysis excluding periods of study-wide suspension of device use) over 13 weeks on CLC vs. 70.0 ± 13.6% and 60.4 ± 17.1% on PLGS (difference = 5.9%; 95% CI 3.6%, 8.3%; P < 0.001). Time >180 mg/dL was lower in the CLC group than PLGS group (difference = −6.0%; 95% CI −8.4%, −3.7%; P < 0.001) while time <54 mg/dL was similar (0.04%; 95% CI −0.05%, 0.13%; P = 0.41). HbA1c after 13 weeks was lower on CLC than PLGS (7.2% [55 mmol/mol] vs. 7.5% [56 mmol/mol], difference −0.34% [−3.7 mmol/mol]; 95% CI −0.57% [−6.2 mmol/mol], −0.11% [1.2 mmol/mol]; P = 0.0035). CONCLUSIONS Following 6 months of CLC, switching to PLGS reduced TIR and increased HbA1c toward their pre-CLC values, while hypoglycemia remained similarly reduced with both CLC and PLGS. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/32471910; hal-03595199; https://hal.umontpellier.fr/hal-03595199Test; PUBMED: 32471910; PUBMEDCENTRAL: PMC7372060 |
| DOI: | 10.2337/dc20-0124 |
| الإتاحة: | https://doi.org/10.2337/dc20-0124Test https://hal.umontpellier.fr/hal-03595199Test |
| رقم الانضمام: | edsbas.D6ADB8A5 |
| قاعدة البيانات: | BASE |
| DOI: | 10.2337/dc20-0124 |
|---|